Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Eur J Pharmacol
2011 Nov 30;6702-3:500-8. doi: 10.1016/j.ejphar.2011.08.053.
Show Gene links
Show Anatomy links
The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic.
Holtman JR
,
Dwoskin LP
,
Dowell C
,
Wala EP
,
Zhang Z
,
Crooks PA
,
McIntosh JM
.
???displayArticle.abstract???
Chronic pain is inadequately managed with currently available classes of analgesic drugs. Recently, peptide antagonists of the α9α10 nicotinic acetylcholine receptor were shown to be analgesic. The present study was conducted to characterize a novel small molecule, non-peptide antagonist at nicotinic receptors. The tetrakis-quaternary ammonium compound ZZ-204G was evaluated for functional activity on cloned nicotinic receptors expressed in Xenopus oocytes. In-vivo efficacy was assessed in rat models of tonic inflammatory pain (formalin test), neuropathic pain (chronic constriction nerve injury), and thermal nociception (tail flick test). ZZ-204G was an antagonist at nicotinic receptors inhibiting the α9α10 subtype with an IC₅₀ of 0.51 (0.35-0.72) nM. Antagonist activity at other nicotinic subtypes (α1β1δε, α2β2, α2β4, α3β2, α3β4, α4β2, α4β4, α6/α3β2β3, α6/α3β4 and α7) was 10-1000-fold lower than at the α9α10 subtype. In competition binding assays, the k(i) of ZZ-204G at γ-aminobutyric acid(A), serotonin(3), γ-aminobutyric acid(B), κ- and μ-opioid receptors was 1000- to >10,000-fold lower than at α9α10 nicotinic receptors. Parenteral administration of ZZ-204G dose-dependently decreased nociceptive behaviors (paw flinches) in the formalin test and mechanical hyperalgesia in the chronic constriction nerve injury model of neuropathic pain. ZZ-204G was not antinociceptive in the tail flick assay. Results from the rotarod assay indicated that lower doses of ZZ-204G that were analgesic did not alter motor function. In summary, ZZ-204G represents a prototype small molecule antagonist for α9α10 nicotinic receptors and provides a novel molecular scaffold for analgesic agents with the potential to treat chronic inflammatory or neuropathic pain.
Arneric,
Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.
2007, Pubmed
Arneric,
Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.
2007,
Pubmed
Azam,
Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.
2009,
Pubmed
Bennett,
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man.
1988,
Pubmed
Buccafusco,
Neuronal nicotinic receptor subtypes: defining therapeutic targets.
2004,
Pubmed
Callaghan,
Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.
2008,
Pubmed
,
Xenbase
Cartier,
A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors.
1996,
Pubmed
,
Xenbase
D'hoedt,
Nicotinic acetylcholine receptors: an overview on drug discovery.
2009,
Pubmed
Elgoyhen,
alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
2001,
Pubmed
,
Xenbase
Ellison,
Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues.
2008,
Pubmed
Gao,
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain.
2010,
Pubmed
Gómez-Casati,
Biophysical and pharmacological characterization of nicotinic cholinergic receptors in rat cochlear inner hair cells.
2005,
Pubmed
Holtman,
The analgesic and toxic effects of nornicotine enantiomers alone and in interaction with morphine in rodent models of acute and persistent pain.
2010,
Pubmed
Klimis,
A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain.
2011,
Pubmed
Livett,
Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor.
2006,
Pubmed
López-Hernández,
Selective inhibition of acetylcholine-evoked responses of alpha7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists.
2009,
Pubmed
,
Xenbase
McIntosh,
Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.
2004,
Pubmed
,
Xenbase
McIntosh,
Alpha9 nicotinic acetylcholine receptors and the treatment of pain.
2009,
Pubmed
,
Xenbase
Medhurst,
Activation of the alpha7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a central site of action.
2008,
Pubmed
Moalem,
Immune and inflammatory mechanisms in neuropathic pain.
2006,
Pubmed
Nevin,
Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins?
2007,
Pubmed
,
Xenbase
Nicke,
Alpha-conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes.
2004,
Pubmed
RANDALL,
A method for measurement of analgesic activity on inflamed tissue.
1957,
Pubmed
Rowley,
Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain.
2010,
Pubmed
Sandall,
A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo.
2003,
Pubmed
Satkunanathan,
Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones.
2005,
Pubmed
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Tjølsen,
The formalin test: an evaluation of the method.
1992,
Pubmed
Vincler,
Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors.
2006,
Pubmed
Vincler,
Neuronal nicotinic receptors as targets for novel analgesics.
2005,
Pubmed
Vincler,
Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain.
2007,
Pubmed
WATZMAN,
SEMIAUTOMATIC SYSTEM FOR TIMING ROTAROD PERFORMANCE.
1964,
Pubmed
Weisstaub,
The alpha9alpha10 nicotinic acetylcholine receptor is permeable to and is modulated by divalent cations.
2002,
Pubmed
,
Xenbase
Wheeler-Aceto,
Standardization of the rat paw formalin test for the evaluation of analgesics.
1991,
Pubmed
Zhang,
Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.
2008,
Pubmed
Zheng,
Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
2007,
Pubmed
